Format

Send to

Choose Destination
See comment in PubMed Commons below
J Rheumatol Suppl. 2010 May;85:53-62. doi: 10.3899/jrheum.091465.

Anti-tumor necrosis factor therapies in immune-mediated rheumatic diseases. Other observations from the clinic.

Author information

1
Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. russell@ualberta.ca

Abstract

To date, over 2 million patients worldwide have been treated with anti-tumor necrosis factor (TNF) therapies, dramatically improving the treatment outcomes of immune-mediated inflammatory diseases (IMID). Observations from clinicians have identified some curious disconnects between clinical and radiographic outcomes, and the paradoxical occurrence of anti-TNF therapy-induced IMID such as psoriasis or reactivation of uveitis and Crohn's disease. These observations point to the need for a better understanding of the mechanisms underlying the ability of anti-TNF therapies to reduce inflammation and how this is linked to the pathogenesis of IMID.

PMID:
20436165
DOI:
10.3899/jrheum.091465
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center